Načítá se...
Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results
OBJECTIVES: Adjuvant chemotherapy decision in patients with hormone receptor positive, HER2 negative breast cancer (BC) is challenging. Ki-67 is widely used for adjuvant therapy decision in BC. The multigene assay EndoPredict (EP) has shown to provide valid and additional information about the risk...
Uloženo v:
| Vydáno v: | Breast |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Elsevier
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7375593/ https://ncbi.nlm.nih.gov/pubmed/31786414 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.breast.2019.11.004 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|